Clinical Trials Logo

Clinical Trial Summary

Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03923634
Study type Interventional
Source Croma-Pharma GmbH
Contact
Status Completed
Phase N/A
Start date October 16, 2018
Completion date October 22, 2019

See also
  Status Clinical Trial Phase
Completed NCT02248844 - Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
Completed NCT02195687 - BOTOX® in the Treatment of Crow's Feet Lines in China Phase 3
Completed NCT01951742 - Dose Finding Study In Subjects With Crow's Feet Phase 2
Completed NCT03721016 - MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) Phase 3
Completed NCT03326856 - ET-01 in Subjects With Lateral Canthal Lines Phase 2
Completed NCT04157686 - MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) Phase 3
Completed NCT03839693 - ET-01 in Subjects With Lateral Canthal Lines, LCL-208 Phase 2
Completed NCT03732833 - MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines Phase 3
Completed NCT00888914 - Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Phase 2
Completed NCT04143854 - Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines Phase 2
Completed NCT01358695 - Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet Phase 2
Completed NCT01124565 - Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Phase 2
Completed NCT00247559 - Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet) Phase 2
Completed NCT01809964 - Clinical Trial to Evaluate ANT-1401 in Crow's Feet Phase 2
Completed NCT03911102 - Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines Phase 2
Completed NCT00968825 - Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Phase 2
Completed NCT04225260 - Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines Phase 3
Completed NCT01064518 - Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults Phase 2
Completed NCT00884234 - Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Phase 2
Completed NCT04249687 - Treatment of Moderate to Severe Lateral Canthal Lines Phase 3